Background: As the number of allergic sensitizations increases the severity of allergic respiratory diseases worsens. Multiple monoallergen immunotherapy can be accompanied by poor treatment adherence and high costs, single multiallergen immunotherapy needs to prove efficacy whilst maintaining a good safety profile. Methods: Observational, retrospective, multicenter study using a 2-pollen single undiluted multiallergen subcutaneous immunotherapy (SCIT) in routine clinical practice in Spain. Patients with rhinoconjunctivitis, with/without controlled asthma, sensitized to grass, olive, Parietaria, Cupressus, plane tree and/or Salsola pollen were included. Primary and secondary clinical efficacy endpoints were quality of life (mini Rhinitis Quality of Life Questionnaire (miniRQLQ)) and visual analogue scale (VAS) respectively. All adverse events were documented. Results: Ten centers included 97 patients, median age 32 years. SCIT treatment included combinations of grass mix with olive, Parietaria, Cupressus, plane tree or Salsola or olive with Parietaria, Cupressus or Salsola. The mean duration of SCIT was 1.8 years with a high treatment adherence (73%). Significant improvement in quality of life, nasal and ocular symptoms, activity limitations and practical problems (p#x3c; 0.0001) and other symptoms (p= 0.024) was observed. Most patients did not develop asthma-like symptoms and a significant improvement of all allergic symptom severity was perceived. VAS showed a significant improvement in rhinoconjunctivitis and asthma by patients and physicians. Twenty-nine patients experienced adverse reactions, 25 had local and 6 had systemic reactions. Conclusions: Single undiluted multiallergen SCIT treatment of two different pollens is efficacious and safe in both children and adults, showing that it is a suitable option for the treatment of polyallergic patients.
Int Arch Allergy Immunol

中文翻译：

---

单一多变应原皮下免疫疗法在多变态反应患者中的安全性和有效性

背景：随着过敏性致敏数量的增加，过敏性呼吸系统疾病的严重程度会恶化。多种单一过敏原免疫疗法可能伴随着治疗依从性差和高成本，单一的多种过敏原免疫疗法需要证明疗效，同时保持良好的安全性。方法：在西班牙的常规临床实践中使用 2 花粉单一未稀释多过敏原皮下免疫疗法 (SCIT) 进行的观察性、回顾性、多中心研究。鼻结膜炎患者，有/没有控制的哮喘，对草、橄榄、Parietaria、柏树、梧桐树和/或 Salsola 花粉敏感。主要和次要临床疗效终点分别是生活质量（迷你鼻炎生活质量问卷（miniRQLQ））和视觉模拟量表（VAS）。记录了所有不良事件。结果：10 个中心包括 97 名患者，中位年龄 32 岁。SCIT 处理包括混合草与橄榄、Parietaria、柏木、梧桐或 Salsola 或橄榄与 Parietaria、柏木或 Salsola 的组合。SCIT 的平均持续时间为 1.8 年，治疗依从性高 (73%)。观察到生活质量、鼻部和眼部症状、活动受限和实际问题 ( p #x3c; 0.0001) 和其他症状 ( p = 0.024) 的显着改善。大多数患者没有出现类似哮喘的症状，并且感知到所有过敏症状严重程度的显着改善。VAS 显示出患者和医生对鼻结膜炎和哮喘的显着改善。不良反应共29例，局部反应25例，全身反应6例。结论：两种不同花粉的单一未稀释多变应原 SCIT 治疗对儿童和成人均有效且安全，表明它是治疗多变应性患者的合适选择。
Int Arch 过敏免疫